HomeBUSINESS
BUSINESS

Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
(Aug.6.2018)

Merck’s Keytruda (pembrolizumab) sales edging out Bristol-Myers Squibb’s Opdivo (nivolumab) figure in April-June made global headlines late last month, but the market leader actually remained unchanged if Ono Pharmaceutical’s share of Asian revenue was added. A Keytruda win looks imminent, nevertheless ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar